Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing

K. A. Birdwell, Brian Decker, J. M. Barbarino, J. F. Peterson, C. M. Stein, W. Sadee, D. Wang, A. A. Vinks, Y. He, J. J. Swen, J. S. Leeder, R. H N Van Schaik, K. E. Thummel, T. E. Klein, K. E. Caudle, I. A M MacPhee

Research output: Contribution to journalArticle

138 Citations (Scopus)

Abstract

Tacrolimus is the mainstay immunosuppressant drug used after solid organ and hematopoietic stem cell transplantation. Individuals who express CYP3A5 (extensive and intermediate metabolizers) generally have decreased doseâ djusted trough concentrations of tacrolimus as compared with those who are CYP3A5 nonexpressers (poor metabolizers), possibly delaying achievement of target blood concentrations. We summarize evidence from the published literature supporting this association and provide dosing recommendations for tacrolimus based on CYP3A5 genotype when known (updates at www.pharmgkb.org).

Original languageEnglish (US)
Pages (from-to)19-24
Number of pages6
JournalClinical Pharmacology and Therapeutics
Volume98
Issue number1
DOIs
StatePublished - Jul 1 2015

Fingerprint

Cytochrome P-450 CYP3A
Pharmacogenetics
Tacrolimus
Genotype
Guidelines
Hematopoietic Stem Cell Transplantation
Immunosuppressive Agents
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Medicine(all)

Cite this

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. / Birdwell, K. A.; Decker, Brian; Barbarino, J. M.; Peterson, J. F.; Stein, C. M.; Sadee, W.; Wang, D.; Vinks, A. A.; He, Y.; Swen, J. J.; Leeder, J. S.; Van Schaik, R. H N; Thummel, K. E.; Klein, T. E.; Caudle, K. E.; MacPhee, I. A M.

In: Clinical Pharmacology and Therapeutics, Vol. 98, No. 1, 01.07.2015, p. 19-24.

Research output: Contribution to journalArticle

Birdwell, KA, Decker, B, Barbarino, JM, Peterson, JF, Stein, CM, Sadee, W, Wang, D, Vinks, AA, He, Y, Swen, JJ, Leeder, JS, Van Schaik, RHN, Thummel, KE, Klein, TE, Caudle, KE & MacPhee, IAM 2015, 'Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing', Clinical Pharmacology and Therapeutics, vol. 98, no. 1, pp. 19-24. https://doi.org/10.1002/cpt.113
Birdwell, K. A. ; Decker, Brian ; Barbarino, J. M. ; Peterson, J. F. ; Stein, C. M. ; Sadee, W. ; Wang, D. ; Vinks, A. A. ; He, Y. ; Swen, J. J. ; Leeder, J. S. ; Van Schaik, R. H N ; Thummel, K. E. ; Klein, T. E. ; Caudle, K. E. ; MacPhee, I. A M. / Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. In: Clinical Pharmacology and Therapeutics. 2015 ; Vol. 98, No. 1. pp. 19-24.
@article{dcc737f0cc1f425a82b8f20904cf5cd0,
title = "Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing",
abstract = "Tacrolimus is the mainstay immunosuppressant drug used after solid organ and hematopoietic stem cell transplantation. Individuals who express CYP3A5 (extensive and intermediate metabolizers) generally have decreased dose{\^a} djusted trough concentrations of tacrolimus as compared with those who are CYP3A5 nonexpressers (poor metabolizers), possibly delaying achievement of target blood concentrations. We summarize evidence from the published literature supporting this association and provide dosing recommendations for tacrolimus based on CYP3A5 genotype when known (updates at www.pharmgkb.org).",
author = "Birdwell, {K. A.} and Brian Decker and Barbarino, {J. M.} and Peterson, {J. F.} and Stein, {C. M.} and W. Sadee and D. Wang and Vinks, {A. A.} and Y. He and Swen, {J. J.} and Leeder, {J. S.} and {Van Schaik}, {R. H N} and Thummel, {K. E.} and Klein, {T. E.} and Caudle, {K. E.} and MacPhee, {I. A M}",
year = "2015",
month = "7",
day = "1",
doi = "10.1002/cpt.113",
language = "English (US)",
volume = "98",
pages = "19--24",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing

AU - Birdwell, K. A.

AU - Decker, Brian

AU - Barbarino, J. M.

AU - Peterson, J. F.

AU - Stein, C. M.

AU - Sadee, W.

AU - Wang, D.

AU - Vinks, A. A.

AU - He, Y.

AU - Swen, J. J.

AU - Leeder, J. S.

AU - Van Schaik, R. H N

AU - Thummel, K. E.

AU - Klein, T. E.

AU - Caudle, K. E.

AU - MacPhee, I. A M

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Tacrolimus is the mainstay immunosuppressant drug used after solid organ and hematopoietic stem cell transplantation. Individuals who express CYP3A5 (extensive and intermediate metabolizers) generally have decreased doseâ djusted trough concentrations of tacrolimus as compared with those who are CYP3A5 nonexpressers (poor metabolizers), possibly delaying achievement of target blood concentrations. We summarize evidence from the published literature supporting this association and provide dosing recommendations for tacrolimus based on CYP3A5 genotype when known (updates at www.pharmgkb.org).

AB - Tacrolimus is the mainstay immunosuppressant drug used after solid organ and hematopoietic stem cell transplantation. Individuals who express CYP3A5 (extensive and intermediate metabolizers) generally have decreased doseâ djusted trough concentrations of tacrolimus as compared with those who are CYP3A5 nonexpressers (poor metabolizers), possibly delaying achievement of target blood concentrations. We summarize evidence from the published literature supporting this association and provide dosing recommendations for tacrolimus based on CYP3A5 genotype when known (updates at www.pharmgkb.org).

UR - http://www.scopus.com/inward/record.url?scp=84962207669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962207669&partnerID=8YFLogxK

U2 - 10.1002/cpt.113

DO - 10.1002/cpt.113

M3 - Article

VL - 98

SP - 19

EP - 24

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 1

ER -